Fluorescence guided resection and glioblastoma in 2015: A review

Lasers in Surgery and Medicine

Volumn 47, Issue 5, 2015, Pages 441-451

  Leroy, Henri Arthur ^a,b,c   Vermandel, Maximilien ^a,b,c   Lejeune, Jean Paul ^a,b,c   Mordon, Serge ^a   Reyns, Nicolas ^a,b,c  

^a U1189 ONCO THAI Image Assisted Laser Therapy for Oncology   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

Author keywords

5 ALA; fluorescence guided resection; high grade glioma; neurosurgery; PPIX

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; CARMUSTINE; PROTOPORPHYRIN; PHOTOSENSITIZING AGENT;

CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CRANIOTOMY; DISEASE CONTROL; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT PLANNING; BRAIN NEOPLASMS; COMPUTER ASSISTED SURGERY; FLUORESCENCE;

AMINOLEVULINIC ACID; BRAIN NEOPLASMS; FLUORESCENCE; GLIOBLASTOMA; HUMANS; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SURGERY, COMPUTER-ASSISTED;

EID: 84932192185     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22359     Document Type: Review

References (101)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.DOI: 10.3322/caac.21166.
2. Omuro A, DeAngelis L,. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-1850.DOI: 10.1001/jama.2013.280319.
3. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S,. A population-based description of glioblastoma multiforme in Los Angeles County 1974-1999. Cancer 2005; 104: 2798-2806.DOI: 10.1002/cncr.21539.
4. Baldi I, Huchet A, Bauchet L, Loiseau H,. Epidemiology of glioblastoma. Neuro-Chirurgie 2010; 56: 433-440.DOI: 10.1016/j.neuchi.2010.07.011.
5. Iacob G, Dinca EB,. Current data and strategy in glioblastoma multiforme. J Med Life 2009; 2: 386-393.
6. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R,. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 2006; 6: 719-732.DOI: 10.1586/14737140.6.5.719.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.DOI: 10.1056/NEJMoa043330.
8. Thomas AA, Omuro A,. Current role of anti-angiogenic strategies for glioblastoma. Curr Treat Options Oncol 2014;DOI: 10.1007/s11864-014-0308-2.
9. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R,. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.DOI: 10.3171/jns.2001.95.2.0190.
10. Sanai N, Polley M-Y, McDermott M, Parsa A, Berger M,. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115: 3-8.DOI: 10.3171/2011.2.jns10998.
11. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al., Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009; 110: 156-162.DOI: 10.3171/2008.4.17536.
12. Stummer W, van den Bent M, Westphal M,. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: New arguments in an old discussion. Acta neurochir 2011; 153: 1211-1218.DOI: 10.1007/s00701-011-1001-x.
13. Stummer W, Kamp MA,. The importance of surgical resection in malignant glioma. Curr Opin Neurol 2009; 22: 645-649.DOI: 10.1097/WCO.0b013e3283320165.
14. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J,. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta neurochir 2003; 145: 5-10.DOI: 10.1007/s00701-002-1030-6.
15. Olson JJ, Ryken T,. Guidelines for the treatment of newly diagnosed glioblastoma: Introduction. J neurooncol 2008; 89: 255-258.DOI: 10.1007/s11060-008-9595-4.
16. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al., The epidemiology of glioma in adults: A "state of the science" review. Neurooncol 2014; 16: 896-913.DOI: 10.1093/neuonc/nou087.
17. Petrecca K, Guiot MC, Panet-Raymond V, Souhami L,. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. Journal of neuro-oncology. 2013; 111: 19-23.DOI: 10.1007/s11060-012-0983-4.
18. Henson JW, Ulmer S, Harris GJ,. Brain tumor imaging in clinical trials. AJNR American journal of neuroradiology. 2008; 29: 419-424.DOI: 10.3174/ajnr.A0963.
19. Eljamel S,. Photodynamic applications in brain tumors: A comprehensive review of the literature. Photodiagnosis Photodyn Ther 2010; 7: 76-85.DOI: 10.1016/j.pdpdt.2010.02.002.
20. de Boer E, Harlaar NJ, Taruttis A, Nagengast WB, Rosenthal EL, Ntziachristos V, et al., Optical innovations in surgery. Br J Surg 2015; 102: e56-72.DOI: 10.1002/bjs.9713.
21. Barone D, Lawrie T, Hart M,. Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev 2014; 1:DOI: 10.1002/14651858.CD009685.pub2.
22. Colditz M, Leyen K, Jeffree R,. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: Theoretical, biochemical and practical aspects. J Clin Neurosci 2012; 19: 1611-1616.DOI: 10.1016/j.jocn.2012.03.013.
23. Johansson A, Palte G, Schnell O, Tonn J-C, Herms J, Stepp H,. 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 2010; 86: 1373-1378.DOI: 10.1111/j.1751-1097.2010.00799.x.
24. Ishihara R, Katayama Y, Watanabe T, Yoshino A, Fukushima T, Sakatani K,. Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomas. Neurol Med Chir 2007; 47: 53-7 discussion 7.
25. Ishizuka M, Abe F, Sano Y, Takahashi K, Inoue K, Nakajima M, et al., Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 2011; 11: 358-365.DOI: 10.1016/j.intimp.2010.11.029.
26. Kennedy JC, Pottier RH,. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14: 275-292.
27. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al., 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997; 79: 2282-2308.
28. Idoate MA, Diez Valle R, Echeveste J, Tejada S,. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 2011; 31: 575-582.DOI: 10.1111/j.1440-1789.2011.01202.x.
29. Wyld L, Tomlinson M, Reed MW, Brown NJ,. Aminolaevulinic acid-induced photodynamic therapy: cellular responses to glucose starvation. Br J Cancer 2002; 86: 1343-1347.DOI: 10.1038/sj.bjc.6600234.
30. Wyld L, Reed MW, Brown NJ,. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. Br J Cancer 1998; 77: 1621-1627.
31. Kanako S KM, Photodynamic medicine in malignant glioma, the reason why ALA induced PpIX is accumulated. Proceedings of the 7th international PDT symposium ed; 2008.
32. Stepp H, Beck T, Pongratz T, Meinel T, Kreth FW, Tonn J, et al., ALA and malignant glioma: Fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 2007; 26: 157-164.
33. Teng L, Nakada M, Zhao SGG, Endo Y, Furuyama N, Nambu E, et al., Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 2011; 104: 798-807.DOI: 10.1038/bjc.2011.12
34. Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE,. Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: Studies in wild-type and null mice. Pharm Res 2004; 21: 1680-1685.
35. Hu Y, Shen H, Keep RF, Smith DE,. Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 2007; 103: 2058-2065.DOI: 10.1111/j.1471-4159.2007.04905.x.
36. Takahashi K, Ikeda N, Nonoguchi N, Kajimoto Y, Miyatake S, Hagiya Y, et al., Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence. Neurooncol 2011; 13: 1234-1243.DOI: 10.1093/neuonc/nor116.
37. Ennis SR, Novotny A, Xiang J, Shakui P, Masada T, Stummer W, et al., Transport of 5-aminolevulinic acid between blood and brain. Brain Res 2003; 959: 226-234.
38. Feigl GC, Ritz R, Moraes M, Klein J, Ramina K, Gharabaghi A, et al., Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg 2010; 113: 352-357.DOI: 10.3171/2009.10.JNS09447.
39. Della Puppa A, De Pellegrin S, d'Avella, Gioffre G, Rossetto M, Gerardi A, et al., 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. Acta neurochirurgica 2013; 155: 965-972. discussion 72. DOI: 10.1007/s00701-013-1660-x.
40. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ,. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
41. EuropeanMedicinesAgency. Gliolan Scientific Discussion. In: Agency EM, editor 2007.
42. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T,. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-576. discussion-76. DOI: 10.1227/01.neu.0000317304.31579.1700006123-200803000-00003 [pii].
43. Ackroyd R, Brown N, Vernon D, Roberts D, Stephenson T, Marcus S, et al., 5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: A pharmacokinetic study. Photochem Photobiol 1999; 70: 656-662.
44. Kelty CJ, Ackroyd R, Brown NJ, Brown SB, Reed MW,. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc 2004; 18: 452-458.DOI: 10.1007/s00464-003-9062-4.
45. Webber J, Kessel D, Fromm D,. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B 1997; 37: 151-153.
46. EuropeanMedicinesAgency. European Medicines Agency. Gliolan. [29th July, 2011]; 2007.
47. Roberts D, Valdes P, Harris B, Fontaine K, Hartov A, Fan X, et al., Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between 5-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 2011; 114: 595-603.DOI: 10.3171/2010.2.jns091322.
48. Eljamel MS,. Fluorescence image-guided surgery of brain tumors: explained step-by-step. Photodiagnosis Photodyn Ther 2008; 5: 260-263.DOI: 10.1016/j.pdpdt.2008.11.003.
49. Tetard MC, Vermandel M, Mordon S, Lejeune JP, Reyns N,. Experimental use of Photodynamic Therapy in high grade gliomas: a review focused on 5-aminolevulinic acid. Photodiagnosis Photodyn Ther 2014; 11: 319-330.DOI: 10.1016/j.pdpdt.2014.04.004.
50. Zimmermann A, Ritsch-Marte M, Kostron H,. MTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 2001; 74: 611-616.
51. Obwegeser A, Jakober R, Kostron H,. Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model. Br J Cancer 1998; 78: 733-738.
52. Acerbi F, Broggi M, Eoli M, Anghileri E, Cavallo C, Boffano C,. Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus 2014; 36: E5.DOI: 10.3171/2013.11.FOCUS13487.
53. Liu JT, Meza D, Sanai N,. Trends in fluorescence image-guided surgery for gliomas. Neurosurgery 2014; 75: 61-71.DOI: 10.1227/NEU.0000000000000344.
54. Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ,. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir 1998; 140: 995-1000.
55. Tonn JC, Stummer W,. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg 2008; 55: 20-26.
56. Colditz M, Jeffree R,. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 1: Clinical, radiological and pathological studies. J Clin Neurosci 2012; 19: 1471-1474.DOI: 10.1016/j.jocn.2012.03.009.
57. Diez Valle R, Tejada Solis S, Idoate Gastearena M, Garcia de Eulate R, Dominguez Echevarri P, Aristu Mendiroz J,. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: Volumetric analysis of extent of resection in single-center experience. J Neurooncol 2011; 102: 105-113.DOI: 10.1007/s11060-010-0296-4.
58. Hebeda KM, Saarnak AE, Olivo M, Sterenborg HJ, Wolbers JG,. 5-Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 brain tumours and in the normal rat brain. Acta Neurochir 1998; 140: 503-512. discussion 12-3.
59. Tejada-Solis S, Aldave-Orzaiz G, Pay-Valverde E, Marigil-Sánchez M, Idoate-Gastearena M, Díez-Valle R,. Prognostic value of ventricular wall fluorescence during 5-aminolevulinic-guided surgery for glioblastoma. Acta neurochirurgica 2012; ++++++++++++++++++ 154: 1997.DOI: 10.1007/s00701-012-1475-1.
60. Stummer W, Tonn Jr-C, Mehdorn H, Nestler U, Franz K, Goetz C, et al., Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 2011; 114: 613-623.DOI: 10.3171/2010.3.jns097.
61. Zhao S, Wu J, Wang C, Liu H, Dong X, Shi C, et al., Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: A systematic review and meta-analysis of prospective studies. PloS one 2013; 8:DOI: 10.1371/journal.pone.0063682.
62. Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H,. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: A one-year experience at a single institutuion. Swiss Med Wkly 2008; 138: 180-185.
63. Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, et al., 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 2010; 116: 1545-1552.DOI: 10.1002/cncr.24903.
64. Slotty P, Siantidis B, Beez T, Steiger H, Sabel M,. The impact of improved treatment strategies on overall survival in glioblastoma patients. Acta Neurochir 2013; 155: 959.DOI: 10.1007/s00701-013-1693-1.
65. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ,. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
66. Diez Valle R, Slof J, Galvan J, Arza C, Romariz C, Vidal C, et al., Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). Neurologia 2014; 29: 131-138.DOI: 10.1016/j.nrl.2013.05.004.
67. Della Puppa A, Ciccarino P, Lombardi G, Rolma G, Cecchin D, Rossetto M,. 5-Aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns. Biomed Res Int 2014; 2014: 232561.DOI: 10.1155/2014/232561.
68. Stummer W, Nestler U, Stockhammer F, Krex D, Kern B, Mehdorn H, et al., Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 2011; 103: 361-370.DOI: 10.1007/s11060-010-0400-9.
69. Cortnum Sr, Laursen J,. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant gliomas-a new treatment modality. Ugeskr Laeger 2013; 175: 570-573.
70. Schucht P, Murek M, Jilch A, Seidel K, Hewer E, Wiest R, et al., Early re-do surgery for glioblastoma is a feasible and safe strategy to achieve complete resection of enhancing tumor. PloS one 2013; 8:DOI: 10.1371/journal.pone.0079846.
71. Jacquesson T, Ducray F, Maucort-Boulch D, Armoiry X, Louis-Tisserand G, Mbaye M, et al., Surgery of high-grade gliomas guided by fluorescence: A retrospective study of 22 patients. Neurochirurgie 2013; 59: 9-16.DOI: 10.1016/j.neuchi.2012.07.002.
72. Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, et al., Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: High-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol 2014; 40: 297-304.DOI: 10.1016/j.ejso.2013.11.022.
73. Pichlmeier U, Bink A, Schackert G, Stummer W, Group ALAGS,. Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neurooncol 2008; 10: 1025-1034.DOI: 10.1215/15228517-2008-052.
74. Diez Valle R, Slof J, Galvin J, Arza C, Romariz C, Vidal C, et al., Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). Neurologia 2013; 29:DOI: 10.1016/j.nrl.2013.05.004.
75. Schucht P, Beck Jr, Abu-Isa J, Andereggen L, Murek M, Seidel K,. Gross total resection rates in contemporary glioblastoma surgery: Results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012; 71: 927.DOI: 10.1227/NEU.0b013e31826d1e6b.
76. Su X, Huang QF, Chen HL, Chen J,. Fluorescence-guided resection of high-grade gliomas: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther 2014; 11: 451-458.DOI: 10.1016/j.pdpdt.2014.08.001.
77. Schucht P, Murek M, Jilch A, Seidel K, Hewer E, Wiest R, et al., Early re-do surgery for glioblastoma is a feasible and safe strategy to achieve complete resection of enhancing tumor. PloS one 2013; 8:DOI: 10.1371/journal.pone.0079846.
78. Kim A, Khurana M, Moriyama Y, Wilson BC,. Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements. J Biomed Opt 2010; 15: 067006.DOI: 10.1117/1.3523616.
79. Haj-Hosseini N, Richter J, Andersson-Engels S, Wårdell K,. Optical touch pointer for fluorescence guided glioblastoma resection using 5-aminolevulinic acid. Lasers Surg Med 2010; 42: 9-14.DOI: 10.1002/lsm.20868.
80. Valdes PA, Leblond F, Kim A, Harris BT, Wilson BC, Fan X, et al., Quantitative fluorescence in intracranial tumor: Implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 2011; 115: 11-17.DOI: 10.3171/2011.2.jns101451.
81. Valdes PA, Jacobs VL, Wilson BC, Leblond F, Roberts DW, Paulsen KD,. System and methods for wide-field quantitative fluorescence imaging during neurosurgery. Opt Lett 2013; 38: 2786-2788.
82. Johansson A, Palte G, Schnell O, Tonn Jr-C Jr-C, Herms J, Stepp H,. 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 2010; 86: 1373-1378.DOI: 10.1111/j.1751-1097.2010.00799.x.
83. Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, et al., Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 2011; 113: 541-547.DOI: 10.1016/j.clineuro.2011.03.008.
84. Tsugu A, Ishizaka H, Mizokami Y, Osada T, Baba T, Yoshiyama M, et al., Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma. World Neurosurg 2011; 76: 120-127.DOI: 10.1016/j.wneu.2011.02.005.
85. Utsuki S, Oka H, Sato S, Shimizu S, Suzuki S, Tanizaki Y, et al., Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir 2007; 47: 210.
86. Rapp M, Kamp M, Steiger H-J, Sabel M,. Endoscopic-Assisted Visualization of 5-Aminolevulinic Acid-Induced Fluorescence in Malignant Glioma Surgery: A Technical Note. World Neurosurg 2013; 82: 277-279. DOI: 10.1016/j.wneu.2013.07.002.
87. Nestler U, Warter A, Cabre P, Manzo N,. A case of late-onset multiple sclerosis mimicking glioblastoma and displaying intraoperative 5-aminolevulinic acid fluorescence. Acta Neurochir (Wien) 2012; 154: 899-901.DOI: 10.1007/s00701-012-1319-z.
88. Ritz R, Feigl GC, Schuhmann MU, Ehrhardt A, Danz S, Noell S, et al., Use of 5-ALA fluorescence guided endoscopic biopsy of a deep-seated primary malignant brain tumor. J Neurosurg 2011; 114: 1410-1413.DOI: 10.3171/2010.11.JNS10250.
89. Tamura Y, Kuroiwa T, Kajimoto Y, Miki Y, Miyatake S, Tsuji M,. Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note. J Neurosurg 2007; 106: 507-510.DOI: 10.3171/jns.2007.106.3.507.
90. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H,. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir 2010; 152: 1711-1719.DOI: 10.1007/s00701-010-0708-4.
91. Valdes PA, Bekelis K, Harris BT, Wilson BC, Leblond F, Kim A, et al., 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo. Neurosurgery 2014; 10 (Suppl 1): 74.DOI: 10.1227/neu.0000000000000117.
92. Cornelius JF, Slotty PJ, El Khatib M, Giannakis A, Senger B, Steiger HJ,. Enhancing the effect of 5-aminolevulinic acid based photodynamic therapy in human meningioma cells. Photodiagnosis Photodyn Ther 2014; 11: 1-6.DOI: 10.1016/j.pdpdt.2014.01.001.
93. Utsuki S, Miyoshi N, Oka H, Miyajima Y, Shimizu S, Suzuki S, et al., Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study. Brain Tumor Pathol 2007; 24: 53-55.DOI: 10.1007/s10014-007-0223-3.
94. Kamp MA, Grosser P, Felsberg Jr, Slotty PJ, Steiger H-JJ, Reifenberger G, et al., 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: A retrospective study. Acta Neurochir 2012; 154: 223.DOI: 10.1007/s00701-011-1200-5.
95. Yoo H, Kim YZ, Nam BH, Shin SH, Yang HS, Lee JS, et al., Reduced local recurrence of a single brain metastasis through microscopic total resection. J Neurosurg 2009; 110: 730-736.DOI: 10.3171/2008.8.jns08448.
96. Beez T, Sarikaya-Seiwert S, Steiger H-JJ, Hanggi D,. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of brain tumors in children-a technical report. Acta Neurochir 2014; 156: 597-604.DOI: 10.1007/s00701-014-1997-9.
97. Macy ME, Birks DK, Barton VN, Chan MH, Donson AM, Kleinschmidt-Demasters BK, et al., Clinical and molecular characteristics of congenital glioblastoma. Neurooncol 2012; 14: 931-941.DOI: 10.1093/neuonc/nos125.
98. Barbagallo GM, Certo F, Heiss K, Albanese V,. 5-ALA fluorescence-assisted surgery in pediatric brain tumors: Report of three cases and review of the literature. Br J Neurosurg 2014;DOI: 10.3109/02688697.2014.913779.
99. Preuss M, Renner C, Krupp W, Christiansen H, Fischer L, Merkenschlager A, et al., The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors. Childs Nerv Syst 2013; 29: 1263-1267.DOI: 10.1007/s00381-013-2159-8.
100. Slof J, Diez Valle R, Galvan J,. Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. Neurologia (Barcelona Spain) 2014;DOI: 10.1016/j.nrl.2013.11.002.
101. Guyotat J, Medico-economic evaluation of surgery guided by fluorescence for the optimization of resection of glioblastomas, https://clinicaltrials.gov/ct2/show/NCT01811121 2013.